In this study, researchers assessed the stability of various formulations in the TrichoConcept™ line for customized alopecia treatment. They found that the combinations remained stable from 14 to 180 days, supporting the use of these vehicles for enhancing therapeutic outcomes in hair loss treatments.
This study evaluated the stability of multiple active ingredients in TrichoSol™ for use in alopecia treatments, finding varying stability durations at room temperature—up to 180 days for some ingredients—supporting its use as a compounding vehicle in personalized therapies.
In this study, researchers assessed the physical-chemical and microbiological stability of various pharmaceutical ingredients in the vehicle TrichoSolTM, finding differing beyond-use dates for the compounds, such as 180 days for cetirizine hydrochloride, but only 90 days for progesterone at higher concentrations.
In this study, using Trichosol™ with Minoxidil (3%) increased the percentage of hair in the anagen growth phase by about 20% over 90 days compared to using Minoxidil alone.
81 citations
,
August 1979 in “Archives of Dermatology” This case report describes a trichofolliculoma with perineural invasion, highlighting a rare and clinically significant finding in a typically benign hair follicle tumor.